<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:53:27Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8151774" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8151774</identifier>
        <datestamp>2021-05-27</datestamp>
        <setSpec>viruses</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Viruses</journal-id>
              <journal-id journal-id-type="iso-abbrev">Viruses</journal-id>
              <journal-id journal-id-type="publisher-id">viruses</journal-id>
              <journal-title-group>
                <journal-title>Viruses</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1999-4915</issn>
              <publisher>
                <publisher-name>MDPI</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8151774</article-id>
              <article-id pub-id-type="pmcid">PMC8151774</article-id>
              <article-id pub-id-type="pmc-uid">8151774</article-id>
              <article-id pub-id-type="pmid">34066231</article-id>
              <article-id pub-id-type="pmid">34066231</article-id>
              <article-id pub-id-type="doi">10.3390/v13050898</article-id>
              <article-id pub-id-type="publisher-id">viruses-13-00898</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dimeglio</surname>
                    <given-names>Chloé</given-names>
                  </name>
                  <xref ref-type="aff" rid="af1-viruses-13-00898">1</xref>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                  <xref rid="c1-viruses-13-00898" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Milhes</surname>
                    <given-names>Marine</given-names>
                  </name>
                  <xref ref-type="aff" rid="af3-viruses-13-00898">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1252-2960</contrib-id>
                  <name>
                    <surname>Loubes</surname>
                    <given-names>Jean-Michel</given-names>
                  </name>
                  <xref ref-type="aff" rid="af4-viruses-13-00898">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3566-0706</contrib-id>
                  <name>
                    <surname>Ranger</surname>
                    <given-names>Noémie</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mansuy</surname>
                    <given-names>Jean-Michel</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trémeaux</surname>
                    <given-names>Pauline</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jeanne</surname>
                    <given-names>Nicolas</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Latour</surname>
                    <given-names>Justine</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nicot</surname>
                    <given-names>Florence</given-names>
                  </name>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Donnadieu</surname>
                    <given-names>Cécile</given-names>
                  </name>
                  <xref ref-type="aff" rid="af3-viruses-13-00898">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8462-3234</contrib-id>
                  <name>
                    <surname>Izopet</surname>
                    <given-names>Jacques</given-names>
                  </name>
                  <xref ref-type="aff" rid="af1-viruses-13-00898">1</xref>
                  <xref ref-type="aff" rid="af2-viruses-13-00898">2</xref>
                </contrib>
              </contrib-group>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Martinez-Sobrido</surname>
                    <given-names>Luis</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Toral</surname>
                    <given-names>Fernando Almazan</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <aff id="af1-viruses-13-00898"><label>1</label>INSERM UMR1291—CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), 31300 Toulouse, France; <email>izopet.j@chu-toulouse.fr</email></aff>
              <aff id="af2-viruses-13-00898"><label>2</label>Virology Laboratory, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, 31300 Toulouse, France; <email>ranger.no@chu-toulouse.fr</email> (N.R.); <email>mansuy.jm@chu-toulouse.fr</email> (J.-M.M.); <email>tremeaux.p@chu-toulouse.fr</email> (P.T.); <email>jeanne.n@chu-toulouse.fr</email> (N.J.); <email>latour.j@chu-toulouse.fr</email> (J.L.); <email>nicot.f@chu-toulouse.fr</email> (F.N.)</aff>
              <aff id="af3-viruses-13-00898"><label>3</label>Genotoul-Genome &amp; Transcriptome—Plateforme Génomique (GeT-PlaGe), US INRAe 1426, 31326 Castanet-Tolosan, France; <email>marine.milhes@inrae.fr</email> (M.M.); <email>cecile.donnadieu@inrae.fr</email> (C.D.)</aff>
              <aff id="af4-viruses-13-00898"><label>4</label>Institut de Mathématiques de Toulouse, Université de Toulouse, 31400 Toulouse, France; <email>loubes@math.univ-toulouse.fr</email></aff>
              <author-notes>
                <corresp id="c1-viruses-13-00898"><label>*</label>Correspondence: <email>dimeglio.c@chu-toulouse.fr</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <volume>13</volume>
              <issue>5</issue>
              <elocation-id>898</elocation-id>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>07</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 by the authors.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <p>The spread of SARS-CoV-2 and the resulting disease COVID-19 has killed over 2.6 million people as of 18 March 2021. We have used a modified susceptible, infected, recovered (SIR) epidemiological model to predict how the spread of the virus in regions of France will vary depending on the proportions of variants and on the public health strategies adopted, including anti-COVID-19 vaccination. The proportion of SARS-CoV-2 variant B.1.1.7, which was not detected in early January, increased to become 60% of the forms of SARS-CoV-2 circulating in the Toulouse urban area at the beginning of February 2021, but there was no increase in positive nucleic acid tests. Our prediction model indicates that maintaining public health measures and accelerating vaccination are efficient strategies for the sustained control of SARS-CoV-2.</p>
              </abstract>
              <kwd-group>
                <kwd>SARS-CoV-2</kwd>
                <kwd>public health</kwd>
                <kwd>statistical model</kwd>
                <kwd>variant B.1.1.7</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1-viruses-13-00898">
              <title>1. Introduction</title>
              <p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in Wuhan, China, in December 2019 spreads mainly by sustained human-to-human transmission [<xref rid="B1-viruses-13-00898" ref-type="bibr">1</xref>]. Its spread was so rapid that the WHO declared the resulting disease a pandemic [<xref rid="B2-viruses-13-00898" ref-type="bibr">2</xref>]. Many countries opted for a strict lockdown in March 2020 to slow the epidemic and protect their health services. However, SARS-CoV-2 resumed its rampage in Europe, including France, at the end of summer 2020. The measures taken by several large cities to limit virus transmission have provided data that can be used to quantify the impact on virus proliferation of measures such as mask wearing, restricting access to public spaces, and curfew [<xref rid="B3-viruses-13-00898" ref-type="bibr">3</xref>]. The French authorities established a new lockdown from 29 October to 28 November, which was followed by a gradual release under strict sanitary conditions, including a 6 p.m. curfew, together with the start of the COVID-19 vaccination campaign in early 2021 [<xref rid="B4-viruses-13-00898" ref-type="bibr">4</xref>]. These vaccines can protect individuals from COVID-19 symptoms and induce population immunity, so reducing SARS-CoV-2 transmission [<xref rid="B5-viruses-13-00898" ref-type="bibr">5</xref>,<xref rid="B6-viruses-13-00898" ref-type="bibr">6</xref>,<xref rid="B7-viruses-13-00898" ref-type="bibr">7</xref>,<xref rid="B8-viruses-13-00898" ref-type="bibr">8</xref>]. However, a new SARS-CoV-2 variant, B.1.1.7 (GR/20I/501Y.V1), emerged in the southeast of England in October 2020 [<xref rid="B9-viruses-13-00898" ref-type="bibr">9</xref>] and has spread to several countries including France since December 2020. Recent studies indicate that this new variant is up to 70% more readily transmissible than the original virus and is responsible for an increase in case numbers [<xref rid="B10-viruses-13-00898" ref-type="bibr">10</xref>,<xref rid="B11-viruses-13-00898" ref-type="bibr">11</xref>], although its real impact on virus dynamics in specific area remains elusive.</p>
              <p>We have evaluated the impact of the increased proportion of SARS-CoV-2 variant B.1.1.7 in positive tests and ranked the impact of health measures such as physical distancing, mass testing, and vaccination on SARS-CoV-2 proliferation using data for the French city of Toulouse.</p>
            </sec>
            <sec id="sec2-viruses-13-00898">
              <title>2. Materials and Methods</title>
              <sec id="sec2dot1-viruses-13-00898">
                <title>2.1. Statistical Model</title>
                <p>Earlier models for SARS-CoV-2 were based on published positive cases and did not take into account the patients’ ages or an evolutive diffusion coefficient [<xref rid="B12-viruses-13-00898" ref-type="bibr">12</xref>,<xref rid="B13-viruses-13-00898" ref-type="bibr">13</xref>]. That is probably why the Johns Hopkins University predictive model underestimated the spread of the virus in Italy and overestimated its spread in France and the UK. Our model is a discretized version of a susceptible–infectious–recovered (SIR) model [<xref rid="B14-viruses-13-00898" ref-type="bibr">14</xref>]. These compartmental models are well suited to studies of the spread of SARS-CoV-2 in different populations [<xref rid="B15-viruses-13-00898" ref-type="bibr">15</xref>,<xref rid="B16-viruses-13-00898" ref-type="bibr">16</xref>]. Our model includes a diffusion/transmission coefficient <inline-formula><mml:math id="mm1"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> that varies with the likelihood of contagion, and two reduction coefficients <inline-formula><mml:math id="mm2"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm3"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> that describe the impact of public health measures on virus transmission. It also includes a parameter <inline-formula><mml:math id="mm4"><mml:mrow><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> that reflects the prevalence of variant B.1.1.7 on the Toulouse urban area, plus a coefficient <inline-formula><mml:math id="mm5"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> that indicates how the proportion of variant influences the number of new infections. The model predicts how the SARS-CoV-2 virus would have evolved and projects the daily percentages of new positive cases. Then, the resulting data can be used to obtain a projection of SARS-CoV-2 seroprevalence in the Toulouse urban area.</p>
                <p>We have used five variables <inline-formula><mml:math id="mm6"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula><mml:math id="mm7"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of healthy people who have not been vaccinated on day <inline-formula><mml:math id="mm8"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm9"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of undetected contagious carriers infected for <inline-formula><mml:math id="mm10"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> days <inline-formula><mml:math id="mm11"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula>. Similarly, <inline-formula><mml:math id="mm12"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>Q</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of detected contagious carriers infected for <inline-formula><mml:math id="mm13"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> days <inline-formula><mml:math id="mm14"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> on day <inline-formula><mml:math id="mm15"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> <inline-formula><mml:math id="mm16"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of people who were immunized by an infection and <inline-formula><mml:math id="mm17"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of people who were immunized by vaccination. We assume that the risk of reinfection by SARS-CoV-2 after a first infection or vaccination escape is negligible.</p>
                <p><inline-formula><mml:math id="mm18"><mml:mrow><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of days a person is contagious and <inline-formula><mml:math id="mm19"><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:math></inline-formula> is the percentage of the population tested each day. <inline-formula><mml:math id="mm20"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of healthy people contacted and infected by a contagious person. We considered two <inline-formula><mml:math id="mm21"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> figures: <inline-formula><mml:math id="mm22"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced><mml:mi>V</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> for variant B.1.1.7 and <inline-formula><mml:math id="mm23"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> for the original SARS-CoV-2 virus. We assumed that they varied over time and peaked when the virus load was maximal: 7 days after the start of infection [<xref rid="B17-viruses-13-00898" ref-type="bibr">17</xref>,<xref rid="B18-viruses-13-00898" ref-type="bibr">18</xref>]. We also assumed that the number of days a person was contagious is equal to the time of infection i.e., 20 days [<xref rid="B17-viruses-13-00898" ref-type="bibr">17</xref>,<xref rid="B19-viruses-13-00898" ref-type="bibr">19</xref>]. For all <inline-formula><mml:math id="mm24"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm25"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>.</mml:mo><mml:mo> </mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mrow><mml:mfenced><mml:mrow><mml:mfrac><mml:mrow><mml:mi>i</mml:mi><mml:mo>−</mml:mo><mml:mn>7</mml:mn></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>20</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
                <p><inline-formula><mml:math id="mm26"><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:math></inline-formula> is the total population at the start of the epidemic phase,<inline-formula><mml:math id="mm27"><mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> is the multiplier for the spread of the UK variant <inline-formula><mml:math id="mm28"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm29"><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the multiplier for the spread of the epidemic throughout public health restriction phases <inline-formula><mml:math id="mm30"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm31"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is the same multiplier during the quarantine period <inline-formula><mml:math id="mm32"><mml:mrow><mml:mrow><mml:mfenced><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>≤</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula>. <inline-formula><mml:math id="mm33"><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm34"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> are set at 1 when there is no restriction or quarantine. The lower the values of <inline-formula><mml:math id="mm35"><mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="mm36"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>, the greater the constraint applied to halt the spread of the virus. Some values of <inline-formula><mml:math id="mm37"><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> and the value of <inline-formula><mml:math id="mm38"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> have been estimated in previous work by correcting the values predicted by the model using real data collected by the Toulouse Virology Laboratory [<xref rid="B3-viruses-13-00898" ref-type="bibr">3</xref>,<xref rid="B20-viruses-13-00898" ref-type="bibr">20</xref>].</p>
                <p><inline-formula><mml:math id="mm39"><mml:mrow><mml:mrow><mml:mo>∀</mml:mo><mml:mo> </mml:mo><mml:mi>n</mml:mi><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mo> </mml:mo><mml:mo>⟦</mml:mo><mml:mi>d</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>+</mml:mo><mml:mo>∞</mml:mo><mml:mo>⟧</mml:mo><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula><inline-formula><mml:math id="mm40"><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> is defined as: <inline-formula><mml:math id="mm41"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi>argmin</mml:mi></mml:mrow><mml:mi>c</mml:mi></mml:munder><mml:msub><mml:mrow><mml:mfenced close="|" open="|"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mfenced><mml:mi>c</mml:mi></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mo> </mml:mo><mml:mo>⟦</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:mi>d</mml:mi><mml:mo>⟧</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
                <p><inline-formula><mml:math id="mm42"><mml:mrow><mml:mrow><mml:mo>∀</mml:mo><mml:mo> </mml:mo><mml:mi>n</mml:mi><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mo> </mml:mo><mml:mo>⟦</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>+</mml:mo><mml:mo>∞</mml:mo><mml:mo>⟧</mml:mo><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> <inline-formula><mml:math id="mm43"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> is defined as <inline-formula><mml:math id="mm44"><mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mo>:</mml:mo><mml:mo> </mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi>argmin</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mfenced close="|" open="|"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>P</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>n</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mfenced><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo> </mml:mo><mml:mo>∈</mml:mo><mml:mo> </mml:mo><mml:mo>⟦</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>⟧</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
                <p>We used data collected by the Toulouse Virology Laboratory from March 2020 to June 2020 to set <inline-formula><mml:math id="mm45"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> to 0.05 [<xref rid="B20-viruses-13-00898" ref-type="bibr">20</xref>]. The values of <inline-formula><mml:math id="mm46"><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> varied according to the public health restrictions implemented in the Toulouse area [<xref rid="B3-viruses-13-00898" ref-type="bibr">3</xref>].</p>
                <p><inline-formula><mml:math id="mm47"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is given by Equation (1)
<disp-formula id="FD1-viruses-13-00898"><label>(1)</label><mml:math id="mm48"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>Q</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>On transition from day <inline-formula><mml:math id="mm49"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> to day <inline-formula><mml:math id="mm50"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, we have:<disp-formula id="FD2-viruses-13-00898"><label>(2)</label><mml:math id="mm51"><mml:mrow><mml:mrow><mml:mo>∀</mml:mo><mml:mo> </mml:mo><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup><mml:mo> </mml:mo><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>According to this equation, the number of undetected contagious carriers on day <inline-formula><mml:math id="mm52"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> is the number of untested, undetected carriers who were infected but not detected on day <inline-formula><mml:math id="mm53"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>.
<disp-formula id="FD3-viruses-13-00898"><label>(3)</label><mml:math id="mm54"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>P</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mi>N</mml:mi></mml:mfrac><mml:mo>.</mml:mo><mml:mfenced close="]" open=" ["><mml:mrow><mml:munder><mml:mstyle mathsize="120%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mi>i</mml:mi></mml:munder><mml:msubsup><mml:mi>P</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup><mml:mo>.</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced><mml:mo>.</mml:mo><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>V</mml:mi></mml:mfenced><mml:mo>.</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:munder><mml:mstyle mathsize="120%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mi>i</mml:mi></mml:munder><mml:msubsup><mml:mi>Q</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup><mml:mo>.</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced><mml:mo>.</mml:mo><mml:mfenced><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>V</mml:mi></mml:mfenced><mml:mo>.</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo> </mml:mo></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>The above equation indicates that the number of new undetected contagious carriers on day <inline-formula><mml:math id="mm55"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> is the number healthy people who were infected by undetected carriers at any stage of infection or by detected carriers at any stage of infection on day <inline-formula><mml:math id="mm56"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>.
<disp-formula id="FD4-viruses-13-00898"><label>(4)</label><mml:math id="mm57"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>Equation (4) indicates that the number of immunized people on day <inline-formula><mml:math id="mm58"><mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> corresponds to the number of people immunized on day <inline-formula><mml:math id="mm59"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> plus those people at the end of infection on day <inline-formula><mml:math id="mm60"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>, whether or not they were tested.</p>
                <p><inline-formula><mml:math id="mm61"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>1</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>(no quarantine on day one, test results needed)
<disp-formula id="FD5-viruses-13-00898"><label>(5)</label><mml:math id="mm62"><mml:mrow><mml:mrow><mml:mo>∀</mml:mo><mml:mo> </mml:mo><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo> </mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>Q</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>P</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msubsup><mml:mo>·</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>Equation (5) defines the number of detected contagious carriers on day <inline-formula><mml:math id="mm63"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> + 1 as the number of detected contagious carriers on day <inline-formula><mml:math id="mm64"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> plus the number of tested but undetected contagious carriers on day <inline-formula><mml:math id="mm65"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>.</p>
                <p>Before 28 January 2021, we set: <inline-formula><mml:math id="mm66"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula></p>
                <p>From 28 January 2021: <disp-formula id="FD6-viruses-13-00898"><label>(6)</label><mml:math id="mm67"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mn>794</mml:mn><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p>
                <p>Equation (6) defines the number of vaccinated people on day <inline-formula><mml:math id="mm68"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> as the number of people vaccinated and immunized on day <inline-formula><mml:math id="mm69"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> (two doses of vaccine) plus those given the second dose of vaccine 7 days before day <inline-formula><mml:math id="mm70"><mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B5-viruses-13-00898" ref-type="bibr">5</xref>]. This number was 794 in the Toulouse urban area, according to the Regional Health Agency [<xref rid="B21-viruses-13-00898" ref-type="bibr">21</xref>].</p>
                <p>We set <inline-formula><mml:math id="mm71"><mml:mrow><mml:mrow><mml:mtext> </mml:mtext><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mn>2.2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> for the original SARS-CoV-2 virus, at its peak, based on a national and regional French study [<xref rid="B22-viruses-13-00898" ref-type="bibr">22</xref>] and WHO international evaluations [<xref rid="B23-viruses-13-00898" ref-type="bibr">23</xref>]. We added 0.4 to the basic reproduction number <inline-formula><mml:math id="mm72"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> to obtain the reproduction number <inline-formula><mml:math id="mm73"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mfenced><mml:mi>V</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> for the variant B.1.1.7 [<xref rid="B24-viruses-13-00898" ref-type="bibr">24</xref>,<xref rid="B25-viruses-13-00898" ref-type="bibr">25</xref>].</p>
                <p>This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation, as well as the experimental conclusions that can be drawn.</p>
              </sec>
              <sec id="sec2dot2-viruses-13-00898">
                <title>2.2. Study Population</title>
                <p>We estimated the initial model settings using data collected by the Toulouse Virology Laboratory (<xref rid="viruses-13-00898-t001" ref-type="table">Table 1</xref>).</p>
                <p>The total number of tests each day was 2500 at most. We assumed that 3.2% of the population of Toulouse urban area (about 1 million; source INSEE) had been infected with SARS-CoV-2 at the end of the first lockdown (11 May 2020) [<xref rid="B26-viruses-13-00898" ref-type="bibr">26</xref>], which implies that there were close to 32,000 immune individuals, <inline-formula><mml:math id="mm74"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> in mid-May. We also assumed that 20% of infections were asymptomatic [<xref rid="B27-viruses-13-00898" ref-type="bibr">27</xref>,<xref rid="B28-viruses-13-00898" ref-type="bibr">28</xref>]. The number of SARS-CoV-2 cases gradually increased from 21 July 2020 (time = 0 for the model). The date <inline-formula><mml:math id="mm75"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:math></inline-formula> corresponds to two periods (February 5 to February 12, 2021, and March 5 to 12 March 2021) for the evaluation of two health measures in addition to the 6 p.m. national curfew: the closure of non-food areas of over 20,000 m<sup>2</sup> (from 31 January) and the closure of the banks in the Garonne river (from February 28). The date <inline-formula><mml:math id="mm76"><mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the period 27 January to 1 February 2021.</p>
                <p>The daily percentage of new SARS-CoV-2 cases was predicted using the initial parameters (<xref rid="viruses-13-00898-t001" ref-type="table">Table 1</xref>). We used the number of cases on the previous day and two contagion parameters <inline-formula><mml:math id="mm77"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>B</mml:mi></mml:mfenced><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mtext> </mml:mtext><mml:mi>and</mml:mi></mml:mrow><mml:mo> </mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>R</mml:mi><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:msubsup><mml:mfenced><mml:mi>V</mml:mi></mml:mfenced><mml:mo stretchy="false">)</mml:mo><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> that varied according to the strain of SARS-CoV-2 on the day of infection, and the constraints in force (quarantine, lockdown, or restrictions). We assumed that COVID-19 vaccination began on 1 January 2021. The theoretical efficacy of vaccination was set at 94%, as stated by the Pfizer trial [<xref rid="B5-viruses-13-00898" ref-type="bibr">5</xref>], and we considered a subject to be immunized 7 days after the second dose (28 days after the first injection).</p>
              </sec>
              <sec id="sec2dot3-viruses-13-00898">
                <title>2.3. SARS-CoV-2 RNA Detection and Sequencing</title>
                <p>Nasopharyngeal swab samples collected at two drive-through testing centers (Toulouse Purpan and Toulouse Rangueil sites) from 8 January 2021 to 7 February 2021 were tested using the ThermoFisher TaqPath RT-PCR assay (Scientific TaqPath COVID-19 Combo Kit, Thermo Fisher, Waltham, USA) after nucleic acid extraction using the MGI automated extraction system (MGI Easy Nucleic Acid Extraction Kit). All positive nasopharyngeal samples with cycle threshold (Ct) values below 28 (Ct ≤ 28 for N-gene) were tested using the Illumina CovidSeq test (COVIDSeq, Illumina, USA) on the Illumina Nova Seq 6000 Sequencing System (Genotoul platform, GeTPlaGe, Toulouse). SARS-CoV-2 sequences were analyzed using the Illumina DRAGEN COVIDSeq test pipeline.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3-viruses-13-00898">
              <title>3. Results</title>
              <sec id="sec3dot1-viruses-13-00898">
                <title>3.1. Evolution of the Proportion of the SARS-CoV-2 Variants</title>
                <p>Sequencing of all the positive nasopharyngeal samples (Ct ≤ 28) showed that the main variants in the Toulouse urban area at the beginning of January were B.1.177 (GV/20E.EU1) with 51% of the total and B.1.160 (GH/20A.EU2) with 20% of the total (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>A). The proportion of the B.1.177 variant decreased during January from 51% to 11% on 7 February (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>E). The proportion of the B.1.160 variant varied between 31.2% and 12.7% during the same period. In contrast, the B.1.1.7 variant, which was not found during the first week in January (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>A), appeared gradually (11% in the week from 11 January to 17 January 2021) (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>B) and became the major form of the virus (60%) in the Toulouse urban area at the beginning of February (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>E). Other notable variants, B.1.351 (GH/20H/501Y.V2, South Africa) and P1 (GR/20J/501Y.V3, Brazil), believed to be highly transmissible and less sensitive to neutralizing antibodies [<xref rid="B29-viruses-13-00898" ref-type="bibr">29</xref>,<xref rid="B30-viruses-13-00898" ref-type="bibr">30</xref>], appeared in early January 2021 but never accounted for more than 3% of the total in positive tests except for the first week of sequencing, which has few samples (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>A).</p>
              </sec>
              <sec id="sec3dot2-viruses-13-00898">
                <title>3.2. Outlook for the Evolution of the SARS-CoV-2 Dynamics in the Urban Area of Toulouse</title>
                <p>The match between the values predicted by the model and the values observed for 21 days over different split periods is given by a goodness-of-fit measure, R<sup>2</sup> = 87%.</p>
                <p>A previous study showed that the 6 p.m. curfew imposed from 20 January 2021 reduced the circulation of SARS-CoV-2 among Toulouse inhabitants by 35% [<xref rid="B31-viruses-13-00898" ref-type="bibr">31</xref>]. The average positive RT-PCR tests was 10.5% between 27 January and 1 February 2021 (<xref ref-type="fig" rid="viruses-13-00898-f002">Figure 2</xref>). We used the sequencing data to estimate how the proportion of SARS-CoV-2 variant B.1.1.7, <inline-formula><mml:math id="mm78"><mml:mrow><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>v</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, changed during the month of January. The B.1.1.7 variant was the major variant (60%) circulating in the Toulouse urban area from 27 January to 1 February (<xref ref-type="fig" rid="viruses-13-00898-f001">Figure 1</xref>E). The hypotheses for its <inline-formula><mml:math id="mm79"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> set out in Methods (<inline-formula><mml:math id="mm80"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>2.6</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> predicted that the percentage of new positive cases tested over this period would be 21.2% if the variant B.1.1.7 was responsible for 100% of SARS-CoV-2 infections. After correction based on the observed data for this interval, its estimated impact on virus dynamics <inline-formula><mml:math id="mm81"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula> is about 2%.</p>
                <p>Vaccination increased the proportion of the Toulouse urban area population immunized against SARS-CoV-2 after January 28. We also used the data for 5–12 February 2021 to assess adherence to the closure of large (&gt;20,000 m<sup>−2</sup>) non-food areas. The 6 p.m. curfew should have increased the number of positive RT-PCR tests to 11–12% by mid-February. Instead, the positive tests plateaued at around 10.5%, when the constraint was greatest (37%). Using these data, and assuming that vaccination continued at the same pace, the percentage of daily new positive cases should slowly increase to 11% at the middle of March 2021 (<xref ref-type="fig" rid="viruses-13-00898-f002">Figure 2</xref>). The closure of banks in the Garonne on 28 February 2021, which made it possible to limit population groupings, provides us with the second set of data to fit our model over the period 5 March to 12 March 2021. The percentage of positive tests varied between 7.5% and 8% during this period, which corresponds to a 41% reduction in virus replication (<xref ref-type="fig" rid="viruses-13-00898-f002">Figure 2</xref>). These constraints plus continued vaccination should limit the percentage of positive tests to 10.9% on 13 February 2021. Then, the spread of SARS-CoV-2 should decrease to 7.8% positive tests on 15 March 2021 and 4.4% on 15 April (<xref ref-type="fig" rid="viruses-13-00898-f002">Figure 2</xref>). In parallel, the proportion of people immunized by natural infection or vaccination should increase from 10.1% on 13 February to 16.3% on 15 April.</p>
              </sec>
              <sec id="sec3dot3-viruses-13-00898">
                <title>3.3. The Parameters Influencing the Spread of SARS-CoV-2</title>
                <p>Our model includes three parameters that influence the spread of the virus: public health measures (person–person barriers, closure of some public spaces, restrictions on store opening, curfews), mass testing, and vaccination. We have evaluated their impact in order to provide a rational basis for public health strategies. We focused on the period following the positive test peak, 14 February to 1 March 2021.</p>
                <p>The barrier measures, testing–tracing–isolation and vaccination, decreased the positive tests from their peak on 13 February to 9.8% on 1 March 2021. Halving the testing capacity but continuing all the other measures would increase the spread of virus to give 11.2% positive tests on 1 March 2021 (purple curve, <xref ref-type="fig" rid="viruses-13-00898-f003">Figure 3</xref>). Similarly, completely stopping mass testing would increase the percentage of positive tests to 12.6% on the same date (blue curve, <xref ref-type="fig" rid="viruses-13-00898-f003">Figure 3</xref>). Without vaccination, but with all the other measures, would have increased the percentage of positive tests after 13 February to reach 12.3% on 1 March 2021 (red curve, <xref ref-type="fig" rid="viruses-13-00898-f003">Figure 3</xref>). Lifting all the barriers on 14 February 2021, even with the continued vaccination and mass testing, would result in contamination exploding to reach 59% on 1 March 2021.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec4-viruses-13-00898">
              <title>4. Discussion</title>
              <p>We have used a discretized SIR model to predict the spread of SARS-CoV-2 infections and evaluated the impact of the SARS-CoV-2 variant B.1.1.7, mass testing, vaccination, and other public health measures. By sequencing all the RT-PCR positive samples with Ct ≤28, we find that the distribution of SARS-CoV-2 strains changed in the Toulouse urban area from January 2021. The Brazilian (P1) and South African (B.1.1.351) variants did not spread, despite being highly transmissible; they accounted for a negligible fraction of the circulating virus. In contrast, the UK variant (B.1.1.7), which did not exist in early January, quickly became the major circulating strains of SARS-CoV-2 (60% at the beginning of February). This rapid growth is similar to that observed in United Kingdom and indicates its great capacity to adapt to its host [<xref rid="B9-viruses-13-00898" ref-type="bibr">9</xref>]. However, there was not a comparable increase in the rate of positive tests, which should have occurred, given its assumed elevated <inline-formula><mml:math id="mm82"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B24-viruses-13-00898" ref-type="bibr">24</xref>]. We deduced that the impact of this variant on virus spreading was limited (2% at most), which would indicate that all the health measures and the testing–tracing–isolation policy are effective on this variant, in contrast to some reports [<xref rid="B10-viruses-13-00898" ref-type="bibr">10</xref>,<xref rid="B11-viruses-13-00898" ref-type="bibr">11</xref>]. These findings are consistent with those reported very recently [<xref rid="B32-viruses-13-00898" ref-type="bibr">32</xref>]. An English study reported a theoretically higher rate of transmissibility for the B.1.1.7 variant than for the other variants but without changes in either severity or hospital dynamics. The study concluded that the health measures that are applied, including social distancing, vaccination, and lockdown, even regional, made it possible to keep the B.1.1.7 variant under control [<xref rid="B32-viruses-13-00898" ref-type="bibr">32</xref>]. Our result also questions the hypothesis underlying the <inline-formula><mml:math id="mm83"><mml:mrow><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> assigned to this variant; it accounts for increased transmissibility, which is not verified by the observed data. Of the three variants, B.1.1.7, B.1.351, and P1 harboring the N501Y mutation in the Spike protein, characterized by nasopharyngeal loads higher than that of the other strains (data not shown), only the B.1.1.7 variant became predominant. A recent study reported that B.1.1.7 dominates over another variant, B.1.351, in geographic areas where both variants co-circulate, and the B.1.1.7 was the first variant introduced in the population [<xref rid="B33-viruses-13-00898" ref-type="bibr">33</xref>]. In the case of the Toulouse metropolitan area, this hypothesis seems difficult to sustain as the circulation of SARS-CoV-2 had already experienced several peaks before the first detection of the English variant and as there was a pre-existing dominant strain, the variant B.1.177. We could also consider that the B.1.1.7 variant could induce more asymptomatic infections than the other variants. This could explain its dominance without affecting the dynamics of positivity rates by RT-PCR tests. However, recent studies showed that there is no greater proportion of asymptomatic cases with the increase in the proportion of the B.1.1.7 variant among circulating strains of SARS-CoV-2 [<xref rid="B32-viruses-13-00898" ref-type="bibr">32</xref>].</p>
              <p>The second lockdown began on 29 October 2020 in France, and it has been gradually relaxed from 28 November with health measures to the epidemic restarting, including a nation-wide 6 p.m. curfew [<xref rid="B31-viruses-13-00898" ref-type="bibr">31</xref>]. We find that the health measures have the greatest impact on the spread of SARS-CoV-2; the rate of positive tests would have increased 6-fold on 1 March if we had stopped all health measures on 14 February. Mass testing has a more moderate impact on virus replication dynamics; the positive test rate would have increased by 14% had we halved the number of tests and by 29% if we had stopped screening altogether. This more moderate impact could well be due to the maintenance of strong physical distancing measures. They contain the spread of the virus whatever the immune status. The vaccination policy pursued in the Toulouse urban area reduced the spread of SARS-CoV-2 by around 25%. As vaccination started at the end of 2020 in the Toulouse urban area, the first impact was not seen until 28 days later. There were signs that vaccination was having an effect on 14 February. Had vaccination begun earlier and more massively, these effects would probably have been more marked [<xref rid="B34-viruses-13-00898" ref-type="bibr">34</xref>]. However, the positive test rate would have been rising after 13 February even without vaccination, and despite the testing and physical distancing. We have assumed that vaccinated people will not transmit SARS-CoV-2 to healthy unvaccinated people, but this is only an hypothesis as phase 3 clinical trials of COVID-19 vaccines were not designed to demonstrate the prevention of transmission [<xref rid="B5-viruses-13-00898" ref-type="bibr">5</xref>,<xref rid="B6-viruses-13-00898" ref-type="bibr">6</xref>,<xref rid="B7-viruses-13-00898" ref-type="bibr">7</xref>]. Nevertheless, recent reports suggest that mRNA vaccines do block SARS-CoV-2 transmission. A study on nearly 1.2 million people, half of whom were vaccinated, confirmed that these vaccines protected 94% of patients against symptomatic forms of the disease [<xref rid="B35-viruses-13-00898" ref-type="bibr">35</xref>]. It also indicates that the vaccine provides up to 90% protection against asymptomatic infections seven days after the second dose of vaccine [<xref rid="B35-viruses-13-00898" ref-type="bibr">35</xref>]. Another study, conducted by the Sheba Medical Center in Israel on nearly 10,000 hospital staff frequently tested after vaccination, found that 85% of the 7214 members given their first dose of vaccine in January were protected 15 to 28 days later [<xref rid="B36-viruses-13-00898" ref-type="bibr">36</xref>]. The overall reduction in asymptomatic infections was around 75%. Two other Israeli studies sought to assess the virus load in vaccinated people still carrying the virus [<xref rid="B37-viruses-13-00898" ref-type="bibr">37</xref>,<xref rid="B38-viruses-13-00898" ref-type="bibr">38</xref>]. They both concluded that vaccination significantly reduced the virus load in those who had become infected. This suggests that anti-SARS-CoV-2 vaccines greatly reduce virus excretion and, therefore, its transmission.</p>
              <p>Our study has several limitations. The forecasts obtained with this SIR-type epidemiological model assume that its parameters remain stable over time. This is why we have chosen to work on local data, which we could configure precisely, and which have the quality of remaining rather stable over time. This is what allows us to obtain an 87% match between real data and simulated data. Parameter estimation in all mathematical models can lead to biased projections. We have attempted to overcome this problem for the parameters <inline-formula><mml:math id="mm84"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>c</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo> </mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm85"><mml:mrow><mml:mover accent="true"><mml:mi>q</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> that account for the impact of public health measures by correcting the predictions with observed data [<xref rid="B3-viruses-13-00898" ref-type="bibr">3</xref>,<xref rid="B20-viruses-13-00898" ref-type="bibr">20</xref>,<xref rid="B31-viruses-13-00898" ref-type="bibr">31</xref>,<xref rid="B34-viruses-13-00898" ref-type="bibr">34</xref>]. We also did this to estimate the impact of the variant B.1.1.7, <inline-formula><mml:math id="mm86"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></inline-formula>, on virus spreading. The estimated virus proliferation rates resulting from the application of various public health measures also assume that the population continues to adhere to these measures over time. Obviously, estimating the impact of vaccination on virus spread assumes that the sociological constraints and the vaccination campaign are widely adhered to, especially among priority populations.</p>
              <p>In conclusion, the emergence of the B.1.1.7 variant led to a rapid alteration in the distribution of circulating strains of SARS-CoV-2. The B.1.1.7 variant accounted for 60% of the circulating SARS-CoV-2 viruses in the Toulouse urban area at the beginning of February, without any increase in the positive test rate. Currently, the B.1.1.7 variant accounts for over 90% of positive tests while the positive test rate is still decreasing. Public health measures and testing–tracing–isolation policies appear to be effective against this variant, as is vaccination. Maintaining public health measures and accelerating vaccination must both be employed to keep SARS-CoV-2 under control.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The English text was edited by Owen Parkes.</p>
            </ack>
            <fn-group>
              <fn>
                <p><bold>Publisher’s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <notes>
              <title>Author Contributions</title>
              <p>C.D. (Chloé Dimeglio) and J.-M.L. contributed to the model design and methodology. P.T., J.-M.M., F.N. and J.I. contributed to data collection. M.M. and C.D. (Cécile Donnadieu) performed sequencing analyses. M.M., N.R., N.J., J.L., C.D. (Cécile Donnadieu) and F.N. contributed to data processing. C.D. (Chloé Dimeglio), N.J., F.N. and J.L. contributed to data analysis. C.D. (Chloé Dimeglio), P.T., F.N. and J.I. contributed to data interpretation. C.D. (Chloé Dimeglio) and J.I. wrote the first draft of the manuscript. All authors contributed to critical revision of the manuscript and all authors have read and agreed to the published version of the manuscript.</p>
            </notes>
            <notes>
              <title>Funding</title>
              <p>This research received no external funding.</p>
            </notes>
            <notes>
              <title>Institutional Review Board Statement</title>
              <p>Not applicable.</p>
            </notes>
            <notes>
              <title>Informed Consent Statement</title>
              <p>Not applicable.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data Availability Statement</title>
              <p>The datasets used and/or analysed during the current study are available from the corresponding author on request.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Conflicts of Interest</title>
              <p>The authors declare no conflict of interest.</p>
            </notes>
            <ref-list>
              <title>References</title>
              <ref id="B1-viruses-13-00898">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Perlman</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Another Decade, Another Coronavirus</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1056/NEJMe2001126</pub-id>
                </element-citation>
              </ref>
              <ref id="B2-viruses-13-00898">
                <label>2.</label>
                <element-citation publication-type="web">
                  <article-title>WHO Virtual press conference on COVID-19—11 March 2020</article-title>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2">https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B3-viruses-13-00898">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dimeglio</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Loubes</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Mansuy</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Izopet</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantifying the impact of public health protection measures on the spread of SARS-CoV-2</article-title>
                  <source>J. Infect.</source>
                  <year>2021</year>
                  <volume>82</volume>
                  <fpage>414</fpage>
                  <lpage>451</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jinf.2020.10.026</pub-id>
                </element-citation>
              </ref>
              <ref id="B4-viruses-13-00898">
                <label>4.</label>
                <element-citation publication-type="web">
                  <article-title>EU Strategy for COVID-19 Vaccines</article-title>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327&amp;uri=CELEX:52020DC0245">https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327&amp;uri=CELEX:52020DC0245</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B5-viruses-13-00898">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Polack</surname>
                      <given-names>F.P.</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Kitchin</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Absalon</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Gurtman</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Lockhart</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Perez</surname>
                      <given-names>J.L.</given-names>
                    </name>
                    <name>
                      <surname>Pérez Marc</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Moreira</surname>
                      <given-names>E.D.</given-names>
                    </name>
                    <name>
                      <surname>Zerbini</surname>
                      <given-names>C.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2020</year>
                  <volume>383</volume>
                  <fpage>2603</fpage>
                  <lpage>2615</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>
                  <?supplied-pmid 33301246?>
                  <pub-id pub-id-type="pmid">33301246</pub-id>
                </element-citation>
              </ref>
              <ref id="B6-viruses-13-00898">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Voysey</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Clemens</surname>
                      <given-names>S.A.C.</given-names>
                    </name>
                    <name>
                      <surname>Madhi</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Weckx</surname>
                      <given-names>L.Y.</given-names>
                    </name>
                    <name>
                      <surname>Folegatti</surname>
                      <given-names>P.M.</given-names>
                    </name>
                    <name>
                      <surname>Aley</surname>
                      <given-names>P.K.</given-names>
                    </name>
                    <name>
                      <surname>Angus</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Baillie</surname>
                      <given-names>V.L.</given-names>
                    </name>
                    <name>
                      <surname>Barnabas</surname>
                      <given-names>S.L.</given-names>
                    </name>
                    <name>
                      <surname>Bhorat</surname>
                      <given-names>Q.E.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK</article-title>
                  <source>Lancet</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <fpage>99</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id>
                </element-citation>
              </ref>
              <ref id="B7-viruses-13-00898">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baden</surname>
                      <given-names>L.R.</given-names>
                    </name>
                    <name>
                      <surname>Rubin</surname>
                      <given-names>E.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Covid-19—The Search for Effective Therapy</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2020</year>
                  <volume>382</volume>
                  <fpage>1851</fpage>
                  <lpage>1852</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMe2005477</pub-id>
                  <?supplied-pmid 32187463?>
                  <pub-id pub-id-type="pmid">32187463</pub-id>
                </element-citation>
              </ref>
              <ref id="B8-viruses-13-00898">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Emary</surname>
                      <given-names>K.R.W.</given-names>
                    </name>
                    <name>
                      <surname>Golubchik</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Aley</surname>
                      <given-names>P.K.</given-names>
                    </name>
                    <name>
                      <surname>Ariani</surname>
                      <given-names>C.V.</given-names>
                    </name>
                    <name>
                      <surname>Angus</surname>
                      <given-names>B.J.</given-names>
                    </name>
                    <name>
                      <surname>Bibi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Blane</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Bonsall</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Cicconi</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Charlton</surname>
                      <given-names>S.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7)</article-title>
                  <source>Lancet</source>
                  <year>2021</year>
                  <volume>397</volume>
                  <fpage>1351</fpage>
                  <lpage>1362</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00628-0</pub-id>
                  <pub-id pub-id-type="pmid">33798499</pub-id>
                </element-citation>
              </ref>
              <ref id="B9-viruses-13-00898">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Volz</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Mishra</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Chand</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Barrett</surname>
                      <given-names>J.C.</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Geidelberg</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Hinsley</surname>
                      <given-names>W.R.</given-names>
                    </name>
                    <name>
                      <surname>Laydon</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Darbrera</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>O’Toole</surname>
                      <given-names>A.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Transmission of SARS-CoV-2 Lineage, B.1.1.7 in England: Insights from linking epidemiological and genetic data</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1101/2020.12.30.20249034</pub-id>
                </element-citation>
              </ref>
              <ref id="B10-viruses-13-00898">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirby</surname>
                      <given-names>T.</given-names>
                    </name>
                  </person-group>
                  <article-title>New variant of SARS-CoV-2 in IK causes surge of COVID-19</article-title>
                  <source>Lancet Respir. Med.</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <fpage>e20</fpage>
                  <lpage>e21</lpage>
                  <pub-id pub-id-type="doi">10.1016/S2213-2600(21)00005-9</pub-id>
                  <pub-id pub-id-type="pmid">33417829</pub-id>
                </element-citation>
              </ref>
              <ref id="B11-viruses-13-00898">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leung</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Shum</surname>
                      <given-names>M.H.</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>G.M.</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>T.T.</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>J.T.</given-names>
                    </name>
                  </person-group>
                  <article-title>Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020</article-title>
                  <source>Euro Surveill.</source>
                  <year>2021</year>
                  <volume>26</volume>
                  <fpage>2002106</fpage>
                  <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.26.1.2002106</pub-id>
                </element-citation>
              </ref>
              <ref id="B12-viruses-13-00898">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wu</surname>
                      <given-names>J.T.</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in wuhan, china: A modelling study</article-title>
                  <source>Lancet</source>
                  <year>2020</year>
                  <volume>395</volume>
                  <fpage>689</fpage>
                  <lpage>697</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30260-9</pub-id>
                  <pub-id pub-id-type="pmid">32014114</pub-id>
                </element-citation>
              </ref>
              <ref id="B13-viruses-13-00898">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>T.M.</given-names>
                    </name>
                    <name>
                      <surname>Rui</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>A mathematical model for simulating the phase-based transmissibility of a novel coronavirus</article-title>
                  <source>Infect. Dis. Poverty</source>
                  <year>2020</year>
                  <volume>9</volume>
                  <fpage>24</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40249-020-00640-3</pub-id>
                  <?supplied-pmid 32111262?>
                  <pub-id pub-id-type="pmid">32111262</pub-id>
                </element-citation>
              </ref>
              <ref id="B14-viruses-13-00898">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kermack</surname>
                      <given-names>W.O.</given-names>
                    </name>
                    <name>
                      <surname>McKendrick</surname>
                      <given-names>A.G.</given-names>
                    </name>
                  </person-group>
                  <article-title>A Contribution to the Mathematical Theory of Epidemics</article-title>
                  <source>Proc. Roy. Soc. Lond. A</source>
                  <year>1927</year>
                  <volume>115</volume>
                  <fpage>700</fpage>
                  <lpage>721</lpage>
                </element-citation>
              </ref>
              <ref id="B15-viruses-13-00898">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooper</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Mondal</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Antonopoulos CG. A SIR model assumption for the spread of COVID-19 in different communities</article-title>
                  <source>Chaos Solitons Fractals</source>
                  <year>2020</year>
                  <volume>139</volume>
                  <fpage>110057</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.chaos.2020.110057</pub-id>
                  <?supplied-pmid 32834610?>
                  <pub-id pub-id-type="pmid">32834610</pub-id>
                </element-citation>
              </ref>
              <ref id="B16-viruses-13-00898">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Estrada</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>COVID-19 and SARS-CoV-2. Modeling the present, looking at the future</article-title>
                  <source>Phys. Rep.</source>
                  <year>2020</year>
                  <volume>10</volume>
                  <fpage>1</fpage>
                  <lpage>51</lpage>
                </element-citation>
              </ref>
              <ref id="B17-viruses-13-00898">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walsh</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Jordan</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Clyne</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Rohde</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Drummond</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Ahern</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Carty</surname>
                      <given-names>P.G.</given-names>
                    </name>
                    <name>
                      <surname>O’Brien</surname>
                      <given-names>K.K.</given-names>
                    </name>
                    <name>
                      <surname>O’Murchu</surname>
                      <given-names>E.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>SARS-CoV-2 detection, viral load and infectivity over the course of an infection</article-title>
                  <source>J. Infect.</source>
                  <year>2020</year>
                  <volume>81</volume>
                  <fpage>357</fpage>
                  <lpage>371</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.067</pub-id>
                  <pub-id pub-id-type="pmid">32615199</pub-id>
                </element-citation>
              </ref>
              <ref id="B18-viruses-13-00898">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lescure</surname>
                      <given-names>F.X.</given-names>
                    </name>
                    <name>
                      <surname>Bouadma</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Nguyen</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Parisey</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Wicky</surname>
                      <given-names>P.-H.</given-names>
                    </name>
                    <name>
                      <surname>Behillil</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Gaymard</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Bouscambert-Duchamp</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Donati</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Le Hingrat</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical and virological data of the first cases of COVID-19 in Europe: A case series</article-title>
                  <source>Lancet Infect. Dis.</source>
                  <year>2020</year>
                  <volume>20</volume>
                  <fpage>697</fpage>
                  <lpage>706</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30200-0</pub-id>
                  <pub-id pub-id-type="pmid">32224310</pub-id>
                </element-citation>
              </ref>
              <ref id="B19-viruses-13-00898">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jaafar</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Aherfi</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Wurtz</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Grimaldier</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Hoang</surname>
                      <given-names>V.T.</given-names>
                    </name>
                    <name>
                      <surname>Colson</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Raoult</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>La Scola</surname>
                      <given-names>B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates</article-title>
                  <source>Clin. Infect. Dis.</source>
                  <year>2020</year>
                  <volume>28</volume>
                  <fpage>ciaa1491</fpage>
                  <pub-id pub-id-type="doi">10.1093/cid/ciaa1491</pub-id>
                </element-citation>
              </ref>
              <ref id="B20-viruses-13-00898">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dimeglio</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Loubes</surname>
                      <given-names>J.-M.</given-names>
                    </name>
                    <name>
                      <surname>Deporte</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Dubois</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Latour</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Mansuy</surname>
                      <given-names>J.-M.</given-names>
                    </name>
                    <name>
                      <surname>Izopet</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France</article-title>
                  <source>J. Infect.</source>
                  <year>2020</year>
                  <volume>81</volume>
                  <fpage>318</fpage>
                  <lpage>356</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.031</pub-id>
                </element-citation>
              </ref>
              <ref id="B21-viruses-13-00898">
                <label>21.</label>
                <element-citation publication-type="web">
                  <article-title>Santé Publique France (2021) COVID-19: Epidemiological update in Occitania on 11 March 2021</article-title>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.santepubliquefrance.fr/regions/occitanie/documents/bulletin-regional/2021/covid-19-point-epidemiologique-en-occitanie-du-11-mars-2021">https://www.santepubliquefrance.fr/regions/occitanie/documents/bulletin-regional/2021/covid-19-point-epidemiologique-en-occitanie-du-11-mars-2021</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B22-viruses-13-00898">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Salje</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Tran Kiem</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Lefrancq</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Courtejoie</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Bosetti</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Paireau</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Andronico</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Hozé</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Richet</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Dubost</surname>
                      <given-names>C.-L.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Estimating the burden of SARS-CoV-2 in France</article-title>
                  <source>Science</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1126/science.abc3517</pub-id>
                </element-citation>
              </ref>
              <ref id="B23-viruses-13-00898">
                <label>23.</label>
                <element-citation publication-type="web">
                  <article-title>WHO Report of the WHO-China Joint Mission on Coronavirus Disease</article-title>
                  <source>(COVID-19)</source>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-Covid-19-final-report.pdf">https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-Covid-19-final-report.pdf</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B24-viruses-13-00898">
                <label>24.</label>
                <element-citation publication-type="web">
                  <article-title>WHO SARS-CoV-2 Variant—United Kingdom of Great Britain and Northern Ireland</article-title>
                  <source>Disease Outbreak News 21 December 2020</source>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/">https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B25-viruses-13-00898">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>N.G.</given-names>
                    </name>
                    <name>
                      <surname>Abbott</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Barnard</surname>
                      <given-names>R.C.</given-names>
                    </name>
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>C.I.</given-names>
                    </name>
                    <name>
                      <surname>Kucharski</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Munday</surname>
                      <given-names>J.D.</given-names>
                    </name>
                    <name>
                      <surname>Pearson</surname>
                      <given-names>C.A.B.</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>T.W.</given-names>
                    </name>
                    <name>
                      <surname>Tully</surname>
                      <given-names>D.C.</given-names>
                    </name>
                    <name>
                      <surname>Washburne</surname>
                      <given-names>A.D.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title>
                  <source>Science</source>
                  <year>2021</year>
                  <volume>9</volume>
                  <pub-id pub-id-type="doi">10.1126/science.abg3055</pub-id>
                </element-citation>
              </ref>
              <ref id="B26-viruses-13-00898">
                <label>26.</label>
                <element-citation publication-type="web">
                  <article-title>INSERM Press Release (October 2020)</article-title>
                  <comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://presse.inserm.fr/premiers-resultats-des-enquetes-de-sante-publique-de-linserm-sur-la-Covid-19-facteurs-de-risque-individuels-et-sociaux/41032/">https://presse.inserm.fr/premiers-resultats-des-enquetes-de-sante-publique-de-linserm-sur-la-Covid-19-facteurs-de-risque-individuels-et-sociaux/41032/</ext-link></comment>
                  <date-in-citation content-type="access-date" iso-8601-date="2021-04-26">(accessed on 26 April 2021)</date-in-citation>
                </element-citation>
              </ref>
              <ref id="B27-viruses-13-00898">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buitrago-Garcia</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Egli-Gany</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Counotte</surname>
                      <given-names>M.J.</given-names>
                    </name>
                    <name>
                      <surname>Hossmann</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Imeri</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Ipekci</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Salanti</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Low</surname>
                      <given-names>N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis</article-title>
                  <source>PLoS Med.</source>
                  <year>2020</year>
                  <volume>17</volume>
                  <elocation-id>e1003346</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pmed.1003346</pub-id>
                  <?supplied-pmid 32960881?>
                  <pub-id pub-id-type="pmid">32960881</pub-id>
                </element-citation>
              </ref>
              <ref id="B28-viruses-13-00898">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meyerowitz</surname>
                      <given-names>E.A.</given-names>
                    </name>
                    <name>
                      <surname>Richterman</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Bogoch</surname>
                      <given-names>I.I.</given-names>
                    </name>
                    <name>
                      <surname>Low</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Cevik</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2</article-title>
                  <source>Lancet Infect. Dis.</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30837-9</pub-id>
                </element-citation>
              </ref>
              <ref id="B29-viruses-13-00898">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tegally</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Wilkinson</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Giovanetti</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Iranzadeh</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Fonseca</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Giandhari</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Doolabh</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Pillay</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>San</surname>
                      <given-names>E.S.</given-names>
                    </name>
                    <name>
                      <surname>Msomi</surname>
                      <given-names>N.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein</article-title>
                  <source>Nature</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1038/s41586-021-03402-9</pub-id>
                  <?supplied-pmid 33690265?>
                  <pub-id pub-id-type="pmid">33690265</pub-id>
                </element-citation>
              </ref>
              <ref id="B30-viruses-13-00898">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faria</surname>
                      <given-names>N.R.</given-names>
                    </name>
                    <name>
                      <surname>Mellan</surname>
                      <given-names>T.A.</given-names>
                    </name>
                    <name>
                      <surname>Whittaker</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Claro</surname>
                      <given-names>I.M.</given-names>
                    </name>
                    <name>
                      <surname>Candido</surname>
                      <given-names>D.d.S.</given-names>
                    </name>
                    <name>
                      <surname>Mishra</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Crispim</surname>
                      <given-names>M.A.E.</given-names>
                    </name>
                    <name>
                      <surname>Sales</surname>
                      <given-names>F.C.</given-names>
                    </name>
                    <name>
                      <surname>Hawryluk</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>McCrone</surname>
                      <given-names>J.T.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1101/2021.02.26.21252554</pub-id>
                </element-citation>
              </ref>
              <ref id="B31-viruses-13-00898">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dimeglio</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Miedougé</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Loubes</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Mansuy</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Izopet</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France</article-title>
                  <source>J. Infect.</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1016/j.jinf.2021.01.021</pub-id>
                </element-citation>
              </ref>
              <ref id="B32-viruses-13-00898">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Graham</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Sudre</surname>
                      <given-names>C.H.</given-names>
                    </name>
                    <name>
                      <surname>May</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Antonelli</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Varsavsky</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Klaser</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Canas</surname>
                      <given-names>L.S.</given-names>
                    </name>
                    <name>
                      <surname>Molteni</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Modat</surname>
                      <given-names>M.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study</article-title>
                  <source>Lancet Public Health</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1016/S2468-2667(21)00055-4</pub-id>
                </element-citation>
              </ref>
              <ref id="B33-viruses-13-00898">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kostaki</surname>
                      <given-names>E.G.</given-names>
                    </name>
                    <name>
                      <surname>Tseti</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Tsiodras</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Pavlakis</surname>
                      <given-names>G.N.</given-names>
                    </name>
                    <name>
                      <surname>Sfikakis</surname>
                      <given-names>P.P.</given-names>
                    </name>
                    <name>
                      <surname>Paraskevis</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation</article-title>
                  <source>Life</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <fpage>375</fpage>
                  <pub-id pub-id-type="pmid">33921938</pub-id>
                </element-citation>
              </ref>
              <ref id="B34-viruses-13-00898">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dimeglio</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Miedougé</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Loubes</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Mansuy</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Izopet</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimating the impact of public health strategies on the spread of SARS-CoV-2: Epidemiological modelling for Toulouse, France</article-title>
                  <source>Rev. Med. Virol.</source>
                  <year>2021</year>
                  <volume>13</volume>
                  <fpage>e2224</fpage>
                  <pub-id pub-id-type="doi">10.1002/rmv.2224</pub-id>
                </element-citation>
              </ref>
              <ref id="B35-viruses-13-00898">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dagan</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Barda</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Kepten</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Miron</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>Perchik</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Katz</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Hernán</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Lipsitch</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Reis</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Balicer</surname>
                      <given-names>R.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2021</year>
                  <volume>384</volume>
                  <fpage>1412</fpage>
                  <lpage>1423</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2101765</pub-id>
                  <pub-id pub-id-type="pmid">33626250</pub-id>
                </element-citation>
              </ref>
              <ref id="B36-viruses-13-00898">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amit</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Regev-Yochay</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Afek</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Kreiss</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Leshem</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients</article-title>
                  <source>Lancet</source>
                  <year>2021</year>
                  <volume>397</volume>
                  <fpage>875</fpage>
                  <lpage>877</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00448-7</pub-id>
                </element-citation>
              </ref>
              <ref id="B37-viruses-13-00898">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Levine-Tiefenbrun</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Yelin</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Katz</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Herzel</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Golan</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Schreiber</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Wolf</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Nadler</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Ben-Tov</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Kuint</surname>
                      <given-names>J.</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Decreased SARS-CoV-2 viral load following vaccination</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1101/2021.02.06.21251283</pub-id>
                </element-citation>
              </ref>
              <ref id="B38-viruses-13-00898">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Petter</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Mor</surname>
                      <given-names>O.</given-names>
                    </name>
                    <name>
                      <surname>Zuckerman</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Oz-Levi</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Younger</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Aran</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Erlich</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Initial real world evidence for lower transmissibility of individuals who have been vaccinated by BNT162b2</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <pub-id pub-id-type="doi">10.1101/2021.02.08.21251329</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="viruses-13-00898-f001" orientation="portrait" position="float">
              <label>Figure 1</label>
              <caption>
                <p>The circulating forms of SARS-CoV-2 on Toulouse urban area during January 2021 and early February. (<bold>A</bold>): week 1 (46 samples), (<bold>B</bold>): week 2 (141 samples), (<bold>C</bold>): week 3 (181 samples), (<bold>D</bold>): week 4 (216 samples), (<bold>E</bold>): week 5 (110 samples).</p>
              </caption>
              <graphic xlink:href="viruses-13-00898-g001"/>
            </fig>
            <fig id="viruses-13-00898-f002" orientation="portrait" position="float">
              <label>Figure 2</label>
              <caption>
                <p>Daily spread of SARS-CoV-2 infection, 21 July 2020 to 5 September 2021.</p>
              </caption>
              <graphic xlink:href="viruses-13-00898-g002"/>
            </fig>
            <fig id="viruses-13-00898-f003" orientation="portrait" position="float">
              <label>Figure 3</label>
              <caption>
                <p>Daily spread of SARS-CoV-2 infection, 1 January 2021 to 1 March 2021 depending on the vaccine strategy and the release of public health measures or testing–tracing from 14 February 2021. Black curve: current situation, purple curve: reducing mass testing by half, blue curve: end of mass testing strategy, red curve: no vaccination strategy.</p>
              </caption>
              <graphic xlink:href="viruses-13-00898-g003"/>
            </fig>
            <table-wrap id="viruses-13-00898-t001" orientation="portrait" position="float">
              <object-id pub-id-type="pii">viruses-13-00898-t001_Table 1</object-id>
              <label>Table 1</label>
              <caption>
                <p>Model initial parameters.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age Group</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% In Toulouse Population. (Source INSEE) </th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">A (Based on Toulouse Data)</th>
                    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
                      <inline-formula>
                        <mml:math id="mm87">
                          <mml:mrow>
                            <mml:mstyle mathvariant="bold">
                              <mml:mrow>
                                <mml:msub>
                                  <mml:mi mathvariant="bold-italic">N</mml:mi>
                                  <mml:mi mathvariant="bold-italic">T</mml:mi>
                                </mml:msub>
                              </mml:mrow>
                            </mml:mstyle>
                          </mml:mrow>
                        </mml:math>
                      </inline-formula>
                    </th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;15 years old</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.8%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15–60 years old</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.2%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.58%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60–74 years old</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.4%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.68%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                  </tr>
                  <tr>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;74 years old</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.54%</td>
                    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
